, differential leukocyte counts did not show any eosinophilia and ESR was 35 mm/h. Circulating filarial antigen test was negative. No systemic involvement was noted.
The worm was removed under topical anesthesia under aseptic precautions.
The patient was treated with oral diethylcarbamazine 50 mg BD and levocetrizine 10 mg for 10 days, prednisolone 40 mg, and topical betamethasone every 2 h tapering over 2 weeks. Postoperatively there was no inflammation or raised IOP. The patient's vision recovered to 20/20 for distance and near.
The worm was examined under a Carl Zeiss microscope with measurement facility. The taxonomy was done based on standard keys. Immunoassays could not be done as the specimen was formalin preserved. We identified a subadult female worm of Brugia sp with the reproductive tract at the head end.
Comment
Filariasis is transmitted by a mosquito. 1 Lymphatic filariasis caused by B. malayi occurs in southwest India, China, Indonesia, Malaysia, Korea, the Philippines, and Vietnam. 2 The ocular manifestations of filariasis are elephantiasis of the eyelids, iritis, retinal hemorrhages, or the presence of microfilaria in the lacrimal gland secretion. 3 We made a diagnosis of live B. malayi in the anterior chamber; however, owing to the lack of systemic involvement, this could be a new species B. phangi. 5 Molecular techniques need to be used to identify this.
Diethylcarbamazine clears microfilaria from the blood and has a limited but definite effect on adult parasites. 2 Our patient responded extremely well to treatment. Appropriate examination, identification, and prompt treatment are of paramount importance. Control is by mosquito eradication. Mansonia species are the major vectors in rural areas. 2 Eye ( with known systemic associations. 1 Current proposed mechanisms for the underlying pathogenesis include leukocyte aggregation by activated complement factor 5 (C5a). 2 As noted by the authors' systematic review, there is currently no established treatment for Purtscher-like retinopathy, although the literature consists of several case reports of treatment with corticosteroids, without certainty as to effect on the clinical course. 1 Herein, we report for the first time a case of Purtscher-like retinopathy treated successfully with intravitreal bevacizumab injection.
Case report
A 51-year-old man presented to the Retina Service at the University of Louisville with sudden nontraumatic loss of vision OD. The patient's medical history included hepatitis C, with chronic pancreatitis and cirrhosis. Best-corrected visual acuity (BCVA) was finger counting OD and 20/30 OS. Fundoscopy revealed cotton wool spots and intraretinal hemorrhages surrounding normal optic discs bilaterally (Figure 1 ). Optical coherence tomography (OCT) showed macular edema more severe on the right eye (Figure 2) . Complete blood count with differential, kidney function tests, CRP, cryoglobulin, and amylase were normal. Serum C5a was elevated at 12.9 ng/ml (normal range 4.7-9.5 ng/ml).
The patient received an intravitreal injection of bevacizumab (1.25 mg/0.05 ml) (Genentech, South San Francisco, CA, USA) OU for the treatment of macular edema. At 3-month follow-up BCVA OD improved to 20/160 with resolution of macular edema in both eyes (Figure 2 ).
Comment
Purtscher-like retinopathy is an uncommon disease associated with various conditions. 3 Treatment with corticosteroids has been proposed, but its effectiveness is still controversial. 1 This is the first case to describe the beneficial anatomical and functional effects of intravitreal bevacizumab for the management of macular edema associated with Purtscher-like retinopathy. We suggest this treatment be considered in similar cases.
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The authors declare no conflict of interest. Purtscher flecken are considered pathognomonic 4 and occur in 63% of Purtscher and Purtscher-like retinopathies (PuR). 3 Nesmith et al report the first case of PuR with improvement of visual acuity, fundoscopic signs, and macular edema after the injection of intravitreal bevacizumab. Anti-VEGF agents may be of value considering PuR's proposed pathological mechanisms, namely in endothelial dysregulation 5 and in precapillary arterioles' occlusion with altered retinal microvascular permeability. 6 However, there must be caution before concluding that bevacizumab is useful in PuR because spontaneous improvement is frequent. In a systematic review regarding Purtscher and Purtscher-like retinopathies, 3 we identified improvement of visual acuity in PuR patients without treatment (there was no statistically significant difference between visual acuity improvement in patients receiving corticosteroids vs no corticosteroids), as well as improvement in OCT findings in 63% of the patients, as normalization of the fundoscopic signs in 40% of the patients with PuR. Observation and treatment of the underlying etiology may continue to be the most reasonable therapeutic option at the moment.
In conclusion, further studies should be performed to ascertain whether there is real benefit in performing a treatment with intravitreal bevacizumab. In fact, an international multicentered trial (given the low incidence of this pathology 7 ) with different treatment arm groups should be initiated, comparing sham injection, intravitreal bevacizumab injection, corticosteroid use, and observation alone.
